Butabarbital Discontinuation: What Providers and Prescribers Need to Know in 2026

Prescribers and clinical pharmacists may be fielding questions from patients who cannot fill Butabarbital prescriptions in 2026. This guide provides a comprehensive clinical overview of Butabarbital's market status, prescribing implications, patient transition protocols, and available alternatives — written for providers, not just patients.

Current Market Status: Discontinued, Not Shortaged

As of 2026, Butabarbital sodium (Butisol Sodium) is permanently discontinued from commercial manufacturing in the United States. Both the 30 mg and 50 mg tablet formulations and the 30 mg/5 mL oral solution are no longer produced by any FDA-registered manufacturer.

The FDA published a formal determination in October 2020 (Federal Register Docket No. FDA-2020-N-2032) confirming that the withdrawal of Butisol Sodium from the market was not for reasons of safety or effectiveness. This determination is clinically significant: it means compounding pharmacies are not legally prohibited from preparing Butabarbital and that providers can continue to prescribe it as a compounded formulation when medically justified.

Unlike an FDA drug shortage — which is tracked on the official shortage database with estimated resolution timelines — this is a voluntary market withdrawal. There are no supply projections, no alternate manufacturers entering the market, and no expected return to retail pharmacy shelves.

Clinical Profile of Butabarbital: A Refresher

Butabarbital is an intermediate-acting barbiturate with the following pharmacological profile:

• Mechanism: Non-selective CNS depressant; binds the GABA-A receptor Cl⁻ ionophore, prolonging channel open time and enhancing inhibitory GABAergic tone; also induces CYP1A2, CYP2C9/10, and CYP3A4
• Onset: 45–60 minutes (oral); Peak concentration: 3–4 hours post oral dose
• Duration: 6–8 hours; Half-life: approximately 100 hours
• DEA Schedule: III (Controlled Substance Code 2100; non-narcotic)
• FDA-approved indications: Short-term insomnia (≤2 weeks), daytime anxiety/sedation (15–30 mg TID–QID), preoperative sedation (50–100 mg 60–90 min pre-procedure)
• Key drug interactions: Potent CYP inducer — clinically significant interactions with warfarin, oral contraceptives, corticosteroids, beta-blockers, and other hepatically metabolized drugs; additive CNS depression with opioids, benzodiazepines, and alcohol

Implications for Prescribers Still Writing Butabarbital Scripts

If you are still prescribing Butabarbital, patients will not be able to fill these prescriptions at standard retail pharmacies. Before writing a new prescription, consider:

1. Is there a compounding pharmacy relationship in place? If the patient does not have an established relationship with a compounding pharmacy, the prescription will create friction and potential confusion.
2. Is the prescription written for a compounded formulation specifically? Prescriptions written for "Butisol Sodium" (the discontinued brand) may need to be reissued with compounding specifications to be accepted by a compounding pharmacy.
3. Is the patient at risk for abrupt discontinuation? If a patient cannot find Butabarbital and has been taking it chronically, abrupt discontinuation poses a seizure risk. Proactive communication with at-risk patients is essential.

Safe Transition Protocols for Current Butabarbital Patients

Given Butabarbital's long half-life (~100 hours), abrupt discontinuation can precipitate withdrawal that may be delayed by several days. Recommended transition approach:

1. Assess current dose and duration of use. Patients on higher doses or longer durations require a more gradual taper.
2. Consider a phenobarbital substitution taper. For patients dependent on Butabarbital, substitution with long-acting phenobarbital (Schedule IV) followed by gradual dose reduction is a well-established protocol.
3. Initiate alternative therapy concurrently when appropriate. For patients transitioning from insomnia management, a Z-drug (zolpidem, eszopiclone) or benzodiazepine (temazepam) may be initiated while tapering the barbiturate, under close clinical supervision.

Compounding as a Bridge: What Providers Should Know

Compounding pharmacies can legally prepare Butabarbital under the conditions of Section 503A of the Federal Food, Drug, and Cosmetic Act, given that Butabarbital's API (butabarbital sodium) is a component of a previously FDA-approved drug that was not withdrawn for safety reasons.

When referring patients to a compounding pharmacy, ensure:

• The pharmacy holds appropriate state licensure for Schedule III controlled substances
• The prescription clearly specifies the compounded formulation (not a brand name)
• Your DEA number is on the prescription — required for Schedule III
• You have verified the compounding pharmacy's accreditation (PCAB accreditation is preferred)

Clinical Alternatives: Comparative Overview

For providers transitioning patients, the following alternatives address the core indications for Butabarbital:

• For insomnia: Zolpidem (Schedule IV, widely available, 5–10 mg QHS); Eszopiclone (Schedule IV, 1–3 mg QHS, approved for longer-term use); Temazepam (Schedule IV, 7.5–30 mg QHS)
• For anxiety/daytime sedation: Lorazepam (Schedule IV, 0.5–2 mg BID–TID); Buspirone (non-scheduled, for chronic anxiety)
• For preoperative sedation: Midazolam IV/IM (Schedule IV, standard of care in most hospital settings); Lorazepam oral (Schedule IV)

How medfinder Supports Your Patients

If your patient needs to find a compounding pharmacy that can fill a Butabarbital prescription, medfinder can help. medfinder calls pharmacies in the patient's area to identify which ones can fill their specific prescription, then texts the results directly to the patient. This removes the burden from both the patient and your office staff. Learn more at medfinder.com/providers.

For a step-by-step guide on helping patients find Butabarbital, see: How to Help Your Patients Find Butabarbital in Stock: A Provider's Guide.